Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03179761 · ClinicalTrials.gov registry record · Phase 2
High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT03179761 is a Phase 2 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 124 participants.
The verdict
NCT03179761, a Phase 2 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
This randomized phase II studies the side effects of high-dose trivalent influenza vaccine or standard-dose quadrivalent inactivated influenza and how well they work in treating adult patients undergoing stem cell transplant. Season influenza can cause more severe infections in patients who have had a stem cell transplant since their immune system doesn't work as well. Influenza vaccine may provide better protection against flu in adults.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Quadrivalent Inactivated Influenza Vaccine
- BIOLOGICAL Trivalent Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2017-10-09 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03179761
The ClinicalTrials.gov registry entry for NCT03179761 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03179761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03179761 about?
NCT03179761 is a clinical study titled "High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients". This randomized phase II studies the side effects of high-dose trivalent influenza vaccine or standard-dose quadrivalent inactivated influenza and how well they work in treating adult patients undergoing stem cell transplant. Season influenza can cause more severe infections in patients who have had...
What is the current status of trial NCT03179761?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2017-10-09. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT03179761?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Quadrivalent Inactivated Influenza Vaccine (BIOLOGICAL), Trivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03179761?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.